Novo Nordisk A/SNVONYSE
Loading
Operating Expenses Over TimeStrong
Percentile Rank93
3Y CAGR+13.9%
5Y CAGR+16.0%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+13.9%/yr
vs +11.9%/yr prior
5Y CAGR
+16.0%/yr
Consistent
Acceleration
+2.0pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
2.1x
Strong expansion
Streak
1 yr
Consecutive declineStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $108.94B | -7.3% |
| 2024 | $117.54B | +25.1% |
| 2023 | $93.92B | +27.4% |
| 2022 | $73.70B | +26.0% |
| 2021 | $58.50B | +12.7% |
| 2020 | $51.89B | +4.9% |
| 2019 | $49.45B | +5.3% |
| 2018 | $46.97B | +4.1% |
| 2017 | $45.10B | -2.3% |
| 2016 | $46.16B | - |